Sugi Predict

Sugi Predict / Compounds / SCHEMBL6465227

SCHEMBL6465227

SCHEMBL6465227

Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCNCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 14/20 1.00
▸ LCK P06239 12/20 1.00
▸ TEK Q02763 11/20 1.00
▸ KDR P35968 6/20 0.82
▸ EGFR P00533 3/20 0.82
▸ FYN P06241 2/20 0.82
▸ LYN P07948 2/20 0.82
▸ CSK P41240 2/20 0.82
▸ BTK Q06187 2/20 0.82
▸ KDM4E B2RXH2 1/20 0.82
▸ MEN1 O00255 1/20 0.82
▸ RGS12 O14924 1/20 0.82
▸ NPC1 O15118 1/20 0.82
▸ GMNN O75496 1/20 0.82
▸ ALDH1A1 P00352 1/20 0.82
▸ LMNA P02545 1/20 0.82
▸ TP53 P04637 1/20 0.82
▸ CYP1A2 P05177 1/20 0.82
▸ CYP3A4 P08684 1/20 0.82
▸ CYP2D6 P10635 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6465660 0.99 SRC (0.98) SRCLCKTEKKDREGFR
SCHEMBL16752225 0.94 SRC (0.89) SRCLCKTEKKDREGFR
SCHEMBL6865210 0.94 SRC (1.00) SRCLCKTEKKDREGFR
SCHEMBL14617844 0.94 SRC (1.00) SRCLCKTEKKDREGFR
Hydrochloric Acid SCHEMBL6462081 0.93 SRC (0.98) SRCLCKTEKKDREGFR
SCHEMBL6462759 0.91 SRC (0.84) SRCLCKTEKKDREGFR
SCHEMBL6462761 0.91 SRC (0.84) SRCLCKTEKKDREGFR
SCHEMBL6465275 0.91 SRC (0.84) SRCLCKTEKKDREGFR
Tert-Butyl Formate SCHEMBL28022044 0.91 SRC (0.83) SRCLCKTEKKDREGFR
SCHEMBL24458610 0.90 SRC (0.96) SRCLCKTEKKDREGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115298180-B Compounds for treating or inhibiting recurrence of acute myeloid leukemia 日本理化学研究所 2025-06-10 — — CN disclosed
US-11963960-B2 Compounds for treating or inhibiting recurrence of acute myeloid leukemia FLASH THERAPEUTICS, LLC (US) 2024-04-23 — — US disclosed
EP-4121430-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA Flash Therapeuttics, LLC (US) 2023-01-25 — — EP disclosed
CN-115298180-A Compounds for treating or inhibiting recurrence of acute myeloid leukemia 富雷旭医疗有限责任公司 2022-11-04 — — CN disclosed
US-20210299128-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA RIKEN (JP) 2021-09-30 — — US disclosed
US-20210299128-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA RIKEN (JP) 2021-09-30 — — US disclosed
WO-2021188417-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA FLASH THERAPEUTICS, LLC (US) 2021-09-23 — — WO disclosed
WO-2021188417-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA FLASH THERAPEUTICS, LLC (US) 2021-09-23 — — WO disclosed
US-10548897-B2 KSR antagonists ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2020-02-04 — — US disclosed
EP-2878601-B1 AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA RIKEN (JP) 2018-03-28 — — EP disclosed
US-9604988-B2 Agent for treating or inhibiting recurrence of acute myeloid leukemia RIKEN (JP) 2017-03-28 — — US disclosed
WO-2016168704-A1 KSR ANTAGONISTS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2016-10-20 — — WO disclosed
US-20150210698-A1 AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA RIKEN (JP) 2015-07-30 — — US disclosed
EP-2878601-A1 AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA Riken (JP) 2015-06-03 — — EP disclosed
US-20050008640-A1 Method of treating transplant rejection ABBOTT LABORATORIES 2005-01-13 — — US disclosed
WO-2004100868-A2 METHOD OF TREATING TRANSPLANT REJECTION ABBOTT LABORATORIES (US) 2004-11-25 — — WO disclosed
US-6713474-B2 SERINE-THREONINE AND TYROSINE KINASE INHIBITORS ABBOTT GMBH & CO. KG (DE) 2004-03-30 — — US disclosed
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-08-14 — — US disclosed
EP-1114053-A1 PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2001-07-11 — — EP disclosed
WO-2000017203-A1 PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2000-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008640-A1 Method of treating transplant rejection LCK, ZAP70, FYN SRC 46/4885LCK 1/4885TEK 1465/4885
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents FLT1, FLT4, TFPI SRC 206/4885LCK 6/4885TEK 22/4885
US-10548897-B2 KSR antagonists KSR1, KSR2, KRAS SRC 133/4885LCK 728/4885TEK 891/4885
US-11963960-B2 Compounds for treating or inhibiting recurrence of acute myeloid leukemia MCL1, FLT3, ABL1 SRC 95/4885LCK 188/4885TEK 622/4885
US-20210299128-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA MCL1, FLT3, ABL1 SRC 95/4885LCK 188/4885TEK 622/4885
US-20150210698-A1 AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA MCL1, BCOR, RUNX1 SRC 395/4885LCK 3635/4885TEK 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.